文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

脓毒症患者肾脏Klotho表达降低,重组Klotho预处理减轻脂多糖攻击小鼠的器官损伤

Renal Klotho is Reduced in Septic Patients and Pretreatment With Recombinant Klotho Attenuates Organ Injury in Lipopolysaccharide-Challenged Mice.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论人脓毒症相关急性肾损伤肾活检及内毒素小鼠模型中肾脏Klotho表达显著降低,重组Klotho预处理可减轻小鼠肾脏和脑的损伤、炎症及内皮活化。

该研究采用前瞻性临床实验室研究,检测脓毒症相关急性肾损伤患者尸检肾活检及对照肾癌全肾切除标本的Klotho表达,并在脂多糖攻击小鼠模型中验证。结果显示脓毒症相关急性肾损伤患者肾脏Klotho信使RNA和蛋白水平显著低于对照,小鼠肾脏和脑同样降低,且与肾损伤标志物中性粒细胞明胶酶相关脂质运载蛋白和肾损伤分子-1升高平行。脂多糖注射前30分钟给予重组Klotho(0.05 mg/kg)可减轻小鼠肾脏和脑的器官损伤、炎症和内皮活化,并减少肾脏中性粒细胞浸润。作者认为系统性Klotho替代可能成为脓毒症患者的器官保护治疗。

要点

  • 脓毒症相关急性肾损伤患者肾活检肾脏Klotho信使RNA和蛋白水平显著低于对照受试者。
  • 脂多糖攻击小鼠肾脏和脑Klotho表达降低,与肾损伤标志物中性粒细胞明胶酶相关脂质运载蛋白和肾损伤分子-1升高平行。
  • 脂多糖(1 mg/kg)注射前30分钟给予重组Klotho(0.05 mg/kg)可减轻小鼠肾脏和脑的器官损伤、炎症和内皮活化。
  • 重组Klotho组小鼠肾脏中性粒细胞浸润较单用脂多糖组减少。
  • 作者认为系统性Klotho替代可能成为脓毒症患者的器官保护治疗。

适用人群与场景

  • 成人脓毒症相关急性肾损伤患者(ICU内死于脓毒症者)的尸检肾活检标本,对照为因肾癌行全肾切除术的患者。
  • 雄性C57BL/6小鼠和Klotho单倍体不足小鼠。

处置流程与药物剂量

  • 小鼠接受脂多糖(0.05 mg/kg)注射,分别于4、8、24小时后处死。
  • 小鼠在脂多糖(1 mg/kg)注射前30分钟接受重组Klotho(0.05 mg/kg)。
  • 以生理盐水处理的小鼠作为对照。

研究设计与关键结果

  • 研究类型为前瞻性临床实验室研究(使用人尸检脓毒症相关急性肾损伤肾活检)及小鼠内毒素血症模型实验室研究。
  • 脓毒症相关急性肾损伤活检肾脏Klotho信使RNA和蛋白水平显著低于对照受试者,该发现在脂多糖攻击小鼠的肾脏和脑中被重现。
  • Klotho表达降低与肾损伤标志物中性粒细胞明胶酶相关脂质运载蛋白和肾损伤分子-1升高平行。
  • 脂多糖注射前给予重组Klotho可减轻小鼠肾脏和脑的器官损伤、炎症和内皮活化。
  • 重组Klotho组小鼠肾脏中性粒细胞浸润较单用脂多糖组减少。

证据类型、等级与局限

  • 证据类型:前瞻性临床实验室研究及小鼠内毒素血症模型实验室研究。
  • 作者结论认为系统性Klotho替代可能潜在地成为脓毒症患者的器官保护治疗。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为系统性Klotho替代可能潜在地成为脓毒症患者的器官保护治疗,以阻止急性炎症性器官损伤。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To determine the applicability of recombinant Klotho to prevent inflammation and organ injury in sepsis in man and mice.

DESIGN: Prospective, clinical laboratory study using "warm" human postmortem sepsis-acute kidney injury biopsies. Laboratory study using a mouse model of endotoxemia.

SETTING: Research laboratory at a university teaching hospital.

SUBJECTS: Adult patients who died of sepsis in the ICU and control patients undergoing total nephrectomy secondary to renal cancer; male C57BL/6 and Klotho haploinsufficient mice.

INTERVENTIONS: Lipopolysaccharide (0.05 mg/kg) injection and kill after 4, 8, and 24 hours. Mice received recombinant Klotho (0.05 mg/kg) 30 minutes prior to lipopolysaccharide (1 mg/kg) injection. Mice treated with saline were included as controls.

MEASUREMENTS AND MAIN RESULTS: Quantitative reverse transcription polymerase chain reaction and immunohistochemical staining were used to quantify Klotho messenger RNA and protein expression in the kidney of sepsis-acute kidney injury patients and the kidney and brain of mice. The messenger RNA and protein expression of damage markers, inflammatory cytokine, chemokines, and endothelial adhesion molecules were also determined in mice. Renal neutrophil influx was quantified. We found significantly lower renal Klotho messenger RNA and protein levels in sepsis-acute kidney injury biopsies than in control subjects. These findings were recapitulated in the kidney and brain of lipopolysaccharide-challenged mice. Decreased Klotho expression paralleled an increase in kidney damage markers neutrophil gelatinase-associated lipocalin and kidney injury molecule-1. Administration of recombinant Klotho prior to lipopolysaccharide injection attenuated organ damage, inflammation and endothelial activation in the kidney and brain of mice. Furthermore, less neutrophils infiltrated into the kidneys of recombinant Klotho mice compared with lipopolysaccharide only treated mice.

CONCLUSIONS: Renal Klotho expression in human sepsis-acute kidney injury and in mouse models of sepsis was significantly decreased and correlated with renal damage. Recombinant Klotho intervention diminished organ damage, inflammation, and endothelial activation in the kidney and brain of lipopolysaccharide-challenged mice. Systemic Klotho replacement may potentially be an organ-protective therapy for septic patients to halt acute, inflammatory organ injury.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Jou-Valencia D, Molema G, Popa E, et al. Renal Klotho is Reduced in Septic Patients and Pretreatment With Recombinant Klotho Attenuates Organ Injury in Lipopolysaccharide-Challenged Mice. Crit Care Med. 2018. PMID: 30239382. doi:10.1097/CCM.0000000000003427

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。